Industry / United Kingdom
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Strong Results Buck Trend For Shire
February 2008 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
UK-based drugmaker Shire has announced positive results for 2007, driven by good performances form its leading products and the emergence of Vyvanse (lisdexamfetamine dimesylate), the attention deficit hyperactivity disorder (ADHD) drug acquired along with US-based firm New River Pharmaceuticals early last year. In 2007, total revenues grew by 36% to US$2.4bn.